Technical Analysis for APGE - Apogee Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | -3.63% | |
| Bullish Engulfing | Bullish | -0.58% | |
| Lower Bollinger Band Walk | Weakness | -0.58% | |
| New 52 Week Low | Weakness | -0.58% | |
| Multiple of Ten Bullish | Other | -0.58% | |
| Outside Day | Range Expansion | -0.58% | |
| Lower Bollinger Band Touch | Weakness | -0.58% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 16 hours ago |
| Possible Inside Day | about 16 hours ago |
| Down 5% | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Gap Down Partially Closed | about 19 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/30/2023
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.54 |
| 52 Week Low | 18.99 |
| Average Volume | 282,827 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 22.14 |
| 20-Day Moving Average | 22.08 |
| 10-Day Moving Average | 21.24 |
| Average True Range | 1.50 |
| RSI (14) | 43.18 |
| ADX | 26.95 |
| +DI | 13.13 |
| -DI | 20.34 |
| Chandelier Exit (Long, 3 ATRs) | 20.90 |
| Chandelier Exit (Short, 3 ATRs) | 23.50 |
| Upper Bollinger Bands | 24.73 |
| Lower Bollinger Band | 19.44 |
| Percent B (%b) | 0.23 |
| BandWidth | 23.93 |
| MACD Line | -0.50 |
| MACD Signal Line | -0.31 |
| MACD Histogram | -0.1874 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.44 | ||||
| Resistance 3 (R3) | 22.45 | 21.87 | 22.14 | ||
| Resistance 2 (R2) | 21.87 | 21.43 | 21.87 | 22.04 | |
| Resistance 1 (R1) | 21.28 | 21.15 | 20.99 | 21.27 | 21.95 |
| Pivot Point | 20.70 | 20.70 | 20.56 | 20.70 | 20.70 |
| Support 1 (S1) | 20.11 | 20.26 | 19.82 | 20.10 | 19.41 |
| Support 2 (S2) | 19.53 | 19.98 | 19.53 | 19.32 | |
| Support 3 (S3) | 18.94 | 19.53 | 19.22 | ||
| Support 4 (S4) | 18.93 |
